Published in Antimicrob Agents Chemother on May 29, 2012
Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12
Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments. World J Gastroenterol (2014) 1.10
Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol (2013) 0.99
Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res (2015) 0.99
Present and future therapies of hepatitis B: From discovery to cure. Hepatology (2015) 0.96
Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res (2015) 0.94
Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med (2015) 0.93
A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. Methods Mol Biol (2013) 0.93
Core protein: A pleiotropic keystone in the HBV lifecycle. Antiviral Res (2015) 0.93
Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B (2014) 0.89
Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection. PLoS One (2014) 0.88
Strategies to eliminate HBV infection. Future Virol (2014) 0.87
DDX3 DEAD-box RNA helicase is a host factor that restricts hepatitis B virus replication at the transcriptional level. J Virol (2014) 0.85
How further suppression of virus replication could improve current HBV treatment. Expert Rev Anti Infect Ther (2013) 0.85
Spinoculation Enhances HBV Infection in NTCP-Reconstituted Hepatocytes. PLoS One (2015) 0.85
Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. Clin Liver Dis (2016) 0.84
Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol (2015) 0.83
Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol (2016) 0.81
The hepatitis B virus ribonuclease H as a drug target. Antiviral Res (2015) 0.81
Engineered external guide sequences are highly effective in inhibiting gene expression and replication of hepatitis B virus in cultured cells. PLoS One (2013) 0.80
New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol (2016) 0.79
Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. Sci Rep (2015) 0.79
High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus. J Clin Microbiol (2013) 0.77
An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients. Med Sci Monit (2014) 0.77
Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators. Antiviral Res (2016) 0.76
Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor. J Virol (2016) 0.76
Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol (2015) 0.76
Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol (2016) 0.75
From HCV To HBV Cure. Liver Int (2017) 0.75
Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection. Ann Transl Med (2016) 0.75
Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol (2016) 0.75
Search for a cure for chronic hepatitis B infection: How close are we? World J Hepatol (2015) 0.75
Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies. Front Immunol (2017) 0.75
Towards the elimination and eradication of hepatitis B. J Virus Erad (2015) 0.75
Manipulation of Regulatory Cells' Responses to Treatments for Chronic Hepatitis B Virus Infection. Hepat Mon (2016) 0.75
Advances and Challenges in Studying Hepatitis B Virus In Vitro. Viruses (2016) 0.75
Treatment of hepatitis B virus: an update. Future Microbiol (2016) 0.75
Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation. World J Gastroenterol (2017) 0.75
Antibody-mediated immunotherapy against chronic hepatitis B virus infection. Hum Vaccin Immunother (2017) 0.75
Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. Eur J Med Chem (2017) 0.75
Drugs in Development for Hepatitis B. Drugs (2017) 0.75
New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection. Gastroenterol Hepatol (N Y) (2017) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature (1979) 15.42
Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A (1987) 8.11
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 6.78
Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A (2002) 4.52
The treatment of chronic viral hepatitis. N Engl J Med (1997) 3.97
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Epidemiology and natural history of hepatitis B. Semin Liver Dis (2005) 3.25
Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J Virol (1988) 3.21
Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology (2009) 3.05
Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother (1997) 2.84
Infection and uptake of duck hepatitis B virus by duck hepatocytes maintained in the presence of dimethyl sulfoxide. Virology (1989) 2.52
Hepatitis B: the virus and disease. Hepatology (2009) 2.48
A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature (2009) 2.33
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Hepatitis B viruses: reverse transcription a different way. Virus Res (2008) 2.06
Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol (2001) 1.98
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A (2003) 1.93
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 1.81
Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol (2007) 1.80
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol (1995) 1.72
New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol (2005) 1.57
Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol (2007) 1.51
Covalently closed circular viral DNA formed from two types of linear DNA in woodchuck hepatitis virus-infected liver. J Virol (1996) 1.45
Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol (2010) 1.33
Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis (2007) 1.28
Identification and characterization of avihepadnaviruses isolated from exotic anseriformes maintained in captivity. J Virol (2005) 1.26
Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res (2006) 1.22
Intracellular transport of hepatitis B virus. World J Gastroenterol (2007) 1.14
Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog (2010) 1.13
Primary human hepatocytes--a valuable tool for investigation of apoptosis and hepatitis B virus infection. J Hepatol (2003) 1.11
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol (2007) 1.10
Evaluation of transcriptional efficiency of hepatitis B virus covalently closed circular DNA by reverse transcription-PCR combined with the restriction enzyme digestion method. J Virol (2005) 1.07
Experimental systems for the study of hepadnavirus and hepatitis delta virus infections. Hepatology (1989) 0.99
Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol (2009) 0.96
Proteolytic conversion of hepatitis B virus e antigen precursor to end product occurs in a postendoplasmic reticulum compartment. J Virol (1991) 0.90
Antiviral sulfonamide derivatives. Mini Rev Med Chem (2004) 0.88
Mechanism for CCC DNA synthesis in hepadnaviruses. PLoS One (2009) 0.88
Chimeric mouse model of hepatitis B virus infection. J Hepatol (2011) 0.87
The insertion domain of the duck hepatitis B virus core protein plays a role in nucleocapsid assembly. Virology (2006) 0.85
The role of the woodchuck model in the treatment of hepatitis B virus infection. Clin Liver Dis (2007) 0.82
Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet? J Hepatol (2009) 0.80
Hepatitis B virus cell culture assays for antiviral activity. Methods Mol Med (2000) 0.77
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol (2004) 6.44
Nanowire transistors without junctions. Nat Nanotechnol (2010) 5.73
Coupled spin and valley physics in monolayers of MoS2 and other group-VI dichalcogenides. Phys Rev Lett (2012) 5.60
Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. J Virol (2003) 4.06
Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol (2010) 3.10
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol (2010) 2.98
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol (2005) 2.70
Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol (2007) 2.40
Optical generation of excitonic valley coherence in monolayer WSe2. Nat Nanotechnol (2013) 2.38
Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res (2009) 2.20
Systems approach identifies an organic nitrogen-responsive gene network that is regulated by the master clock control gene CCA1. Proc Natl Acad Sci U S A (2008) 2.17
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
Electrical control of neutral and charged excitons in a monolayer semiconductor. Nat Commun (2013) 1.99
Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol (2008) 1.96
Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res (2006) 1.93
Replication of a cytopathic strain of bovine viral diarrhea virus activates PERK and induces endoplasmic reticulum stress-mediated apoptosis of MDBK cells. J Virol (2002) 1.93
Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol (2007) 1.80
Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2009) 1.79
Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem (2004) 1.78
Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn (2004) 1.62
Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci U S A (2003) 1.58
Cellular and virological mechanisms of HBV drug resistance. J Hepatol (2005) 1.57
SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology (2005) 1.55
A suite of tools and application notes for in vivo protein interaction assays using bioluminescence resonance energy transfer (BRET). Plant J (2006) 1.43
The Arabidopsis repressor of light signaling, COP1, is regulated by nuclear exclusion: mutational analysis by bioluminescence resonance energy transfer. Proc Natl Acad Sci U S A (2004) 1.37
Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol (2010) 1.33
Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol (2007) 1.33
Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res (2013) 1.29
Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol (2008) 1.28
Molecular virology of hepatitis B virus for clinicians. Clin Liver Dis (2007) 1.28
A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob Agents Chemother (2007) 1.27
Identification and characterization of avihepadnaviruses isolated from exotic anseriformes maintained in captivity. J Virol (2005) 1.26
Experimental realization of quantum games on a quantum computer. Phys Rev Lett (2002) 1.25
Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays. Antiviral Res (2006) 1.22
Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J Mol Biol (2010) 1.22
Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog (2013) 1.22
SKIP is a component of the spliceosome linking alternative splicing and the circadian clock in Arabidopsis. Plant Cell (2012) 1.21
Ultrafast hot-carrier-dominated photocurrent in graphene. Nat Nanotechnol (2012) 1.20
Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol (2010) 1.18
Mutant Enpp1asj mice as a model for generalized arterial calcification of infancy. Dis Model Mech (2013) 1.17
Magnetoelectric effects and valley-controlled spin quantum gates in transition metal dichalcogenide bilayers. Nat Commun (2013) 1.16
Reasons to consider earlier treatment of chronic HBV infections. Gut (2011) 1.15
N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem (2008) 1.14
Immunogenicity of the outer domain of a HIV-1 clade C gp120. Retrovirology (2007) 1.13
Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12
Antiviral effect of interferon lambda against West Nile virus. Antiviral Res (2009) 1.12
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway. J Virol (2007) 1.10
Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection. J Virol (2010) 1.10
The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res (2012) 1.10
The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis (2011) 1.10
Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res (2010) 1.09
Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J Virol (2010) 1.08
Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology (2010) 1.08
Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics (2004) 1.06
Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann N Y Acad Sci (2008) 1.05
Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother (2009) 1.04